Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 80,000 target

Generic Database of Very Low Birth Weight Infants

NICHD Neonatal Research Network

NCT00063063

Recruiting 68,000 target

Follow-up Visit of High Risk Infants

NICHD Neonatal Research Network

NCT00009633

Recruiting 20,000 target

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Freenome Holdings

NCT06122077

Recruiting Phase 4 10,742 target

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Ohio State University

NCT06468202

Recruiting 8,000 target

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Massachusetts General Hospital

NCT04916210

Recruiting Phase 3 5,200 target

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting Phase 3 4,390 target

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

Recruiting 4,000 target

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Natera

NCT06808880

Recruiting Phase 3 4,000 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting 3,291 target

Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

Duke University

NCT06815536

Recruiting 3,110 target

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Mayo Clinic

NCT05051722

Recruiting 3,000 target

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Duke University

NCT01915511

Recruiting NA 1,605 target

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Concept Medical

NCT06271590

Recruiting Phase 3 1,216 target

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Bristol-Myers Squibb

NCT05827016

Recruiting Phase 3 1,200 target

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT

Major Extremity Trauma Research Consortium

NCT04678154

Recruiting Phase 4 1,094 target

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

ModernaTX

NCT06585241

Recruiting Phase 3 1,000 target

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

Major Extremity Trauma Research Consortium

NCT07006675

Recruiting Phase 3 1,000 target

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting Phase 3 1,000 target

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Philip Spinella

NCT06070350

Recruiting Phase 3 970 target

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Direct Biologics

NCT05354141

Recruiting Phase 4 832 target

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

ModernaTX

NCT07089706

Recruiting Phase 3 822 target

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Regeneron Pharmaceuticals

NCT06091254

Recruiting Phase 3 770 target

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Merck Sharp & Dohme

NCT06824467

Recruiting 760 target

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Zimmer Biomet

NCT05787821

Recruiting Phase 4 700 target

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis Pharmaceuticals

NCT05803941

Recruiting Phase 3 621 target

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

BioNTech SE

NCT06712355

Recruiting Phase 3 614 target

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Merck Sharp & Dohme

NCT06170788

Recruiting Phase 3 586 target

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Bristol-Myers Squibb

NCT06976203

Recruiting NA 584 target

Zimmer Biomet Shoulder Arthroplasty PMCF

Zimmer Biomet

NCT04984291

Recruiting Phase 3 556 target

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Merck Sharp & Dohme

NCT06074588

Recruiting Phase 3 528 target

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Melt Pharmaceuticals

NCT06383273

Recruiting NA 500 target

Mississippi Delta Community Care Home Visits Program

Jackson State University

NCT07006324

Recruiting NA 500 target

Encore PFO Closure Device - The PerFOrm Trial

Encore Medical

NCT05537753

Recruiting NA 500 target

Cord Clamping Among Neonates With Congenital Heart Disease

Carl Backes, MD

NCT06153459

Recruiting NA 492 target

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Concept Medical

NCT05908331

Recruiting NA 486 target

Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

University of Alabama at Birmingham

NCT06420531

Recruiting Phase 3 470 target

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Regeneron Pharmaceuticals

NCT06149286

Recruiting Phase 3 460 target

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

NCT06614192

Recruiting Phase 3 454 target

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Biogen

NCT06935357

Recruiting Phase 3 450 target

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

AbbVie

NCT05711394

Recruiting NA 420 target

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

Columbia University

NCT06472206

Recruiting Phase 3 420 target

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

AbbVie

NCT06810505

Recruiting Phase 3 400 target

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Reprieve Cardiovascular

NCT06898515

Recruiting NA 400 target

Mississippi Community Engagement Alliance (MS CEAL): Fostering Community Solutions

University of Mississippi Medical Center

NCT07071064

Recruiting Phase 3 400 target

Randomized Withdrawal Study in Patients With Schizophrenia

Vanda Pharmaceuticals

NCT06961968

Recruiting Phase 2 389 target

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

Pfizer

NCT05431088

Recruiting Phase 3 382 target

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

Mayo Clinic

NCT07100990

Recruiting NA 382 target

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

City of Hope Medical Center

NCT06196008

Recruiting Phase 2 380 target

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Atom Therapeutics Co.

NCT07145229

Recruiting Phase 3 360 target

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genmab

NCT06508658

Recruiting NA 350 target

Incremental Hemodialysis: The TwoPlus Trial

Wake Forest University Health Sciences

NCT05828823

Recruiting Phase 2 338 target

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

OHB Neonatology

NCT03253263

Recruiting NA 334 target

Distal Radius Interventions for Fracture Treatment

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05131685

Recruiting Phase 3 330 target

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Gedeon Richter

NCT03817502

Recruiting Phase 3 316 target

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

NICHD Neonatal Research Network

NCT06679855

Recruiting Phase 3 315 target

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Novartis Pharmaceuticals

NCT06439082

Recruiting Phase 3 312 target

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

University of Maryland, Baltimore

NCT05615844

Recruiting Phase 3 300 target

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

Agitated Solutions

NCT06938347

Recruiting 300 target

Lysosomal Acid Lipase (LAL) Deficiency Registry

Alexion Pharmaceuticals

NCT01633489

Recruiting NA 300 target

Intervention to Enhance PrEP Persistence

Brown University

NCT06872307

Recruiting NA 300 target

Jackson Heart Study Women's Hypertension Study

NYU Langone Health

NCT06511479

Recruiting Phase 3 300 target

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

BeOne Medicines

NCT06742996

Recruiting Phase 2 300 target

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Draig Therapeutics

NCT07300969

Recruiting Phase 2 300 target

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Exciva

NCT07284472

Recruiting NA 300 target

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

Laminate Medical Technologies

NCT06516653

Recruiting Phase 3 274 target

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Bristol-Myers Squibb

NCT06951711

Recruiting Phase 3 266 target

Pivotal Study of Voro Urologic Scaffold

Levee Medical

NCT06873581

Recruiting Phase 3 264 target

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Alebund Pharmaceuticals

NCT06933472

Recruiting NA 261 target

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

SoniVie

NCT06559891

Recruiting Phase 3 260 target

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

Octapharma

NCT04867837

Recruiting Phase 2 260 target

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Sanofi

NCT06637631

Recruiting Phase 3 256 target

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Laekna Limited

NCT04851613

Recruiting NA 250 target

Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare

Jackson State University

NCT06481631

Recruiting Phase 2 249 target

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Loxo Oncology

NCT06588478

Recruiting Phase 2 240 target

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Apellis Pharmaceuticals

NCT07215390

Recruiting Phase 3 240 target

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Incyte Corporation

NCT06832618

Recruiting Phase 3 236 target

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

VistaGen Therapeutics

NCT06615557

Recruiting Phase 1 225 target

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Janssen Research & Development

NCT05379595

Recruiting Phase 2 220 target

Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

University of Minnesota

NCT05758246

Recruiting Phase 2 204 target

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Eli Lilly and Company

NCT07169851

Recruiting NA 200 target

A Mobile Gaming App to Improve Adherence to PrEP

Rhode Island Hospital

NCT05762705

Recruiting NA 200 target

The PERSEVERE Study

Inari Medical

NCT06588634

Recruiting Phase 3 200 target

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

AstraZeneca

NCT05692180

Recruiting NA 200 target

Esprit BTK Post-Approval Study

Abbott Medical Devices

NCT06656364

Recruiting Phase 1 200 target

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Oxford BioTherapeutics

NCT04064359

Recruiting Phase 3 192 target

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease

Sanofi

NCT06975865

Recruiting Phase 2 180 target

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

AbbVie

NCT06628310

Recruiting Phase 3 180 target

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

AstraZeneca

NCT07007793

Recruiting NA 180 target

Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

W.L.Gore & Associates

NCT06556654

Recruiting NA 175 target

SPYRAL GEMINI Pilot Study

Medtronic Vascular

NCT06907147

Recruiting Phase 3 173 target

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Pfizer

NCT05568719

Recruiting Phase 2 165 target

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Novartis Pharmaceuticals

NCT07217067

Recruiting Phase 2 160 target

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

EyeBiotech

NCT07205887

Recruiting Phase 3 160 target

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Pfizer

NCT05261139

Recruiting 150 target

STRIVE Post-Market Registry Study

Olympus Corporation of the Americas

NCT04302272

Recruiting Phase 4 140 target

Prescription of Letrozole for Uterine Myoma

University of California, San Francisco

NCT06143631

Recruiting NA 132 target

Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds

NuScience Medical Biologics

NCT06918561

Recruiting Phase 4 132 target

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Upsher-Smith Laboratories

NCT04748601

Recruiting NA 132 target

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

NuScience Medical Biologics

NCT06938685

Recruiting NA 130 target

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

Omeza

NCT07161830

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →